One Wealth Capital Management LLC Takes $943,000 Position in Eli Lilly and Company (NYSE:LLY)

One Wealth Capital Management LLC acquired a new position in Eli Lilly and Company (NYSE:LLY) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 1,221 shares of the company’s stock, valued at approximately $943,000.

A number of other institutional investors and hedge funds have also bought and sold shares of LLY. Spartan Planning & Wealth Management acquired a new position in shares of Eli Lilly and Company in the 4th quarter valued at $574,000. Diversified Trust Co lifted its position in shares of Eli Lilly and Company by 7.2% during the 4th quarter. Diversified Trust Co now owns 14,660 shares of the company’s stock worth $11,318,000 after buying an additional 989 shares during the period. Norman Fields Gottscho Capital Management LLC boosted its stake in Eli Lilly and Company by 1.4% in the 4th quarter. Norman Fields Gottscho Capital Management LLC now owns 1,480 shares of the company’s stock valued at $1,143,000 after buying an additional 20 shares in the last quarter. ShankerValleau Wealth Advisors Inc. acquired a new stake in shares of Eli Lilly and Company in the 4th quarter valued at $239,000. Finally, Ables Iannone Moore & Associates Inc. bought a new stake in shares of Eli Lilly and Company in the 4th quarter worth about $899,000. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Trading Up 0.9 %

Eli Lilly and Company stock traded up $6.74 during mid-day trading on Tuesday, hitting $771.84. 2,739,602 shares of the company’s stock were exchanged, compared to its average volume of 2,570,720. The company’s 50 day simple moving average is $791.18 and its 200-day simple moving average is $862.49. The company has a quick ratio of 0.97, a current ratio of 1.27 and a debt-to-equity ratio of 2.03. The firm has a market capitalization of $732.72 billion, a P/E ratio of 83.44, a PEG ratio of 2.99 and a beta of 0.41. Eli Lilly and Company has a fifty-two week low of $609.59 and a fifty-two week high of $972.53.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Wednesday, October 30th. The company reported $1.18 earnings per share for the quarter, missing the consensus estimate of $1.52 by ($0.34). Eli Lilly and Company had a net margin of 20.48% and a return on equity of 71.08%. The business had revenue of $11.44 billion for the quarter, compared to the consensus estimate of $12.09 billion. During the same quarter last year, the firm earned $0.10 EPS. The company’s revenue for the quarter was up 20.4% on a year-over-year basis. On average, equities analysts anticipate that Eli Lilly and Company will post 13.18 earnings per share for the current year.

Eli Lilly and Company Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, March 10th. Stockholders of record on Friday, February 14th will be given a dividend of $1.50 per share. This is an increase from Eli Lilly and Company’s previous quarterly dividend of $1.30. The ex-dividend date of this dividend is Friday, February 14th. This represents a $6.00 annualized dividend and a dividend yield of 0.78%. Eli Lilly and Company’s dividend payout ratio is currently 64.86%.

Eli Lilly and Company announced that its board has initiated a share buyback plan on Monday, December 9th that allows the company to repurchase $15.00 billion in outstanding shares. This repurchase authorization allows the company to purchase up to 2% of its stock through open market purchases. Stock repurchase plans are typically a sign that the company’s leadership believes its shares are undervalued.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on LLY shares. Redburn Atlantic raised Eli Lilly and Company to a “hold” rating in a report on Monday, November 4th. JPMorgan Chase & Co. upped their target price on shares of Eli Lilly and Company from $1,050.00 to $1,100.00 and gave the stock an “overweight” rating in a research report on Friday, September 13th. Bank of America restated a “buy” rating and issued a $997.00 price objective on shares of Eli Lilly and Company in a research report on Tuesday, December 10th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $885.00 price objective on shares of Eli Lilly and Company in a research report on Monday, September 16th. Finally, StockNews.com upgraded Eli Lilly and Company from a “hold” rating to a “buy” rating in a research report on Wednesday, January 1st. Four investment analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $1,002.22.

Insider Buying and Selling

In related news, CAO Donald A. Zakrowski sold 900 shares of Eli Lilly and Company stock in a transaction that occurred on Friday, November 8th. The stock was sold at an average price of $803.38, for a total value of $723,042.00. Following the sale, the chief accounting officer now owns 5,480 shares of the company’s stock, valued at approximately $4,402,522.40. This trade represents a 14.11 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.13% of the stock is currently owned by company insiders.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.